Covishield Vaccine Carries Slightly Higher Risk Of Bleeding Disorders: Study

A group of researchers reported that people receiving the COVID vaccine made by Oxford-AstraZeneca, also known as Covishield in India, had a slightly increased risk of a bleeding disorder and possibly other rare blood problems

A group of researchers reported that people receiving the COVID vaccine made by Oxford-AstraZeneca, also known as Covishield in India, had a slightly increased risk of a bleeding disorder and possibly other rare blood problems.

The study findings have been published in the journal Nature Medicine, it was found that 2.53 million adults in Scotland who received their first doses of either the AstraZeneca vaccine or the one made by Pfizer-BioNTech. About 1.7 million of the shots were the AstraZeneca vaccine.

However, the study found no increased risk of blood disorders with the Pfizer-BioNTech vaccine.

The AstraZeneca vaccine has been authorized by the European Medicines Agency, the European Union’s top drug regulator, as well as many countries outside the bloc but not authorized for use in the United States. But reports show rare clotting and bleeding disorders in younger adults, some fatal that led a number of countries to restrict the vaccine’s use to older people, and a few to drop it altogether.

According to a new study found that the AstraZeneca vaccine was linked to a slight increase in the risk of a disorder called immune thrombocytopenic purpura, or ITP, which can cause bruising in some cases but also serious bleeding in others. The findings showed that risk was estimated at 1.13 cases per 100,000 people receiving their first dose, up to 27 days after vaccination. That estimate would be in addition to the typical incidence in the United Kingdom before the vaccine came into use, which was estimated at six to nine cases per 100,000

However, the researchers said, the condition is treatable and none of the cases in the vaccinated people were fatal. Along with that they emphasized that the benefits of the vaccine far outweighed the small risk, and noted that COVID itself is far more likely than the vaccine to cause ITP.

But the researchers also wrote that even though the risks from the AstraZeneca vaccine were small, “alternative vaccines for individuals at low COVID-19 risk might be warranted when supply allows.”

It is not surprising to find ITP in a few vaccine recipients, the researchers said, noting that small increases in the risk have also occurred with the vaccination for measles, mumps and rubella, and the shots for hepatitis B and flu.

Facebook Comments